ArticleFrontiers in endocrinology2024
The atherogenic index of plasma is associated with an increased risk of diabetes in non-obese adults: a cohort study.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The correlation between the trajectory of plasma atherosclerosis-inducing index in the examination population and the risk of developing metabolic dysfunction-associated steatotic liver disease.Frontiers in endocrinology · 2026Article
- Oxidative dyslipidemia in early pregnancy: integrating atherogenic index of plasma (AIP) and uric acid (UA) to refine preeclampsia risk stratification.Frontiers in pharmacology · 2026Article
- Combined association of triglyceride-glucose index and the atherogenic index of plasma with the incidence of cardiovascular diseases among middle-aged and older population.Cardiovascular diabetology · 2025Article
- Beyond blood pressure and glucose: exploring potential biochemical predictors of cardiovascular disease risk in patients with type 2 diabetes mellitus and co-morbid hypertension.BMC endocrine disorders · 2025Article
- Association between atherogenic index of plasma and risk of type 2 diabetes mellitus and the mediating effect of BMI: a comparative analysis in Chinese and Japanese populations.Diabetology & metabolic syndrome · 2025Article
- Commentary: The atherogenic index of plasma is associated with an increased risk of diabetes in non-obese adults: a cohort study.Frontiers in endocrinology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the relationship between the atherogenic index of plasma (AIP) and diabetes risk in Chinese non-obese adults. This is important because the incidence of diabetes is significant in non-obese populations, and evidence regarding this association is limited. Methods: We conducted a retrospective cohort study with 82,977 Chinese non-obese adults. We used Cox proportional hazards regression to assess the relationship between baseline AIP levels and diabetes incidence. We also employed cubic spline functions and smooth curve fitting to investigate potential nonlinear relationships. Sensitivity and subgroup analyses were conducted to validate our findings. Results: The median follow-up duration for these participants was 3.10 years, during which 1,041 subjects (1.25%) were diagnosed with diabetes. Adjusted analyses demonstrated a strong positive association between AIP and the risk of diabetes onset (HR 2.07; 95% CI: 1.63-2.63; p < 0.001). The risk of diabetes increased with higher AIP quartiles, especially between the highest (Q4) and lowest (Q1) quartiles (adjusted HR 1.55; 95% CI: 1.27-1.89). We also identified a nonlinear relationship between AIP and diabetes risk. Sensitivity and subgroup analyses confirmed these findings. Furthermore, E-value analysis indicated that the results were robust against unmeasured confounding variables. Conclusion: Our findings highlight a positive, nonlinear association between AIP and diabetes risk in Chinese non-obese adults. Lowering triglycerides (TG) or increasing high-density lipoprotein cholesterol (HDL-C) levels may help reduce this risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.